<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25895" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Nitrates</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lee</surname>
            <given-names>Peter M.</given-names>
          </name>
          <aff>California Northstate University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gerriets</surname>
            <given-names>Valerie</given-names>
          </name>
          <aff>California Northstate University College of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Peter Lee declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Valerie Gerriets declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25895.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Nitrates are useful in the management and treatment of angina. They are a group of medications that cause vasodilation by donating nitric oxide. This activity reviews the indications, action, and contraindications for nitrates as a valuable agent in the management of angina and other cardiovascular diseases.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of nitrates.</p></list-item><list-item><p>Describe the adverse effects of nitrates.</p></list-item><list-item><p>Review the appropriate monitoring and toxicity of nitrates.</p></list-item><list-item><p>Outline inter-professional team strategies for improving care coordination and communication to advance nitrate use and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25895&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25895">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25895.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Nitrates are a class of medications (not to be confused with the byproduct of nitrogen fertilizers) that cause vasodilation by donating nitric oxide (NO).<xref ref-type="bibr" rid="article-25895.r1">[1]</xref> Nitrates exert their effects by dilating venous vessels, coronary arteries, and small arterioles; its maximal vasodilation is in the venous vessels.<xref ref-type="bibr" rid="article-25895.r2">[2]</xref></p>
        <p>Nitrates were first discovered in 1847 as a treatment for chest pain.<xref ref-type="bibr" rid="article-25895.r1">[1]</xref><xref ref-type="bibr" rid="article-25895.r2">[2]</xref> The type of nitrates used and the administration route differs depending on the type of cardiovascular disease. The purpose of nitrate use is multifaceted. For patients with stable and predictable angina, long-acting nitrate can be used as prophylaxis, increasing exercise tolerance in patients.<xref ref-type="bibr" rid="article-25895.r3">[3]</xref> This effect can be beneficial since patients with coronary artery disease tend to have other co-morbidities. For patients with acute anginal pain, short-acting nitrates are useful for symptom relief.<xref ref-type="bibr" rid="article-25895.r3">[3]</xref></p>
        <p>The use of nitrates is indicated in the following cardiovascular diseases: angina pectoris, acute coronary syndrome, arterial hypertension, and heart failure.<xref ref-type="bibr" rid="article-25895.r1">[1]</xref><xref ref-type="bibr" rid="article-25895.r2">[2]</xref></p>
        <p>The main types of nitrates are as followed<xref ref-type="bibr" rid="article-25895.r4">[4]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Nitroglycerin (NTG) &#x02013; angina pectoris (treatment/prophylaxis), acute coronary syndrome, heart failure, hypertension</p>
          </list-item>
          <list-item>
            <p>Isosorbide mononitrate (ISMN) &#x02013; chronic angina pectoris (treatment)</p>
          </list-item>
          <list-item>
            <p>Isosorbide dinitrate (ISDN) &#x02013; angina pectoris (treatment/prophylaxis)</p>
          </list-item>
          <list-item>
            <p>Pentaerythrityl tetranitrate (PETN) &#x02013; <italic toggle="yes">Not commonly used in the United States</italic></p>
          </list-item>
          <list-item>
            <p>Erythrityl tetranitrate (ETN) &#x02013; <italic toggle="yes">Not commonly used in the United States</italic></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25895.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Nitrates exert their pharmacological effect by being activated by mitochondrial or cytosolic aldehyde dehydrogenase (ALDH2) into nitric oxide (NO), an endothelium-derived relaxing factor (EDRF).<xref ref-type="bibr" rid="article-25895.r2">[2]</xref> NO is generally produced by the endothelium to dilate the blood vessels; however, endothelial dysfunction in diseases such as atherosclerosis can deplete NO levels.<xref ref-type="bibr" rid="article-25895.r2">[2]</xref> When administered, nitrates convert to NO, which then activates soluble guanylate cyclase.<xref ref-type="bibr" rid="article-25895.r2">[2]</xref> This action results in increased levels of intracellular cyclic guanosine monophosphate (cGMP) and its dependent protein kinases, such as cGMP-dependent protein kinase I (cGK-I). cGK-I inhibits inositol-1,4,5-trisphosphate-dependent calcium release. The decreased intracellular calcium levels subsequently inhibit myosin light chain kinase, and the unphosphorylated myosin light chain causes myosin head to detach from actin, resulting in smooth muscle relaxation.<xref ref-type="bibr" rid="article-25895.r5">[5]</xref> The NO-cGMP-cGK-I signaling pathway causes vasorelaxation, platelet disaggregation, and prevention of platelet adhesion.<xref ref-type="bibr" rid="article-25895.r2">[2]</xref><xref ref-type="bibr" rid="article-25895.r6">[6]</xref></p>
        <p>The venodilation increases the venous capacitance and lowers the preload; this subsequently lowers the left ventricular end-diastolic pressure, resulting in a reduction in myocardium workload, which decreases the oxygen demand of the heart.<xref ref-type="bibr" rid="article-25895.r2">[2]</xref><xref ref-type="bibr" rid="article-25895.r6">[6]</xref> At higher doses, nitrates can also exert significant coronary artery dilation, allowing blood flow to ischemic areas during coronary artery occlusion and vasospastic angina.<xref ref-type="bibr" rid="article-25895.r7">[7]</xref></p>
      </sec>
      <sec id="article-25895.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Nitrates have many different forms with various routes of administration.<xref ref-type="bibr" rid="article-25895.r3">[3]</xref> Nitroglycerin, also known as glyceryl trinitrate (GTN), can be administered as a patch, ointment, capsule, spray, intravenous infusion, or a sublingual tablet.<xref ref-type="bibr" rid="article-25895.r3">[3]</xref> Sublingual nitroglycerin is the therapy of choice for acute anginal episodes since it avoids first-pass metabolism, allowing for immediate and short anginal relief.<xref ref-type="bibr" rid="article-25895.r3">[3]</xref> Transdermal, ointment, and spray are other options with similar efficacy but are less popular.<xref ref-type="bibr" rid="article-25895.r3">[3]</xref> The capsule form of nitroglycerin has a longer duration of action and require larger doses. Intravenous nitroglycerin is useful for hypertensive emergencies.<xref ref-type="bibr" rid="article-25895.r2">[2]</xref><xref ref-type="bibr" rid="article-25895.r3">[3]</xref></p>
        <p>Other forms of commonly used nitrates include isosorbide dinitrate, isosorbide mononitrate, and isosorbide mononitrate sustained-release (SR). These forms are taken orally and have a longer duration of action. However, due to hepatic metabolism, the oral forms require relatively larger doses.<xref ref-type="bibr" rid="article-25895.r3">[3]</xref><xref ref-type="bibr" rid="article-25895.r7">[7]</xref></p>
        <p>Below are commonly prepared forms of nitrates<xref ref-type="bibr" rid="article-25895.r3">[3]</xref><xref ref-type="bibr" rid="article-25895.r4">[4]</xref><xref ref-type="bibr" rid="article-25895.r8">[8]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Nitroglycerin
<list list-type="bullet"><list-item><p>Sublingual tablet &#x02013; 0.3 to 0.6 mg, up to 1.5 mg as needed a day</p></list-item><list-item><p>Transdermal patch &#x02013; 0.2 &#x02013; 0.8 mg/h, one patch a day (remove at night for 12h)</p></list-item><list-item><p>Ointment &#x02013; 7.5 &#x02013; 40 mg a day</p></list-item><list-item><p>Capsule &#x02013; 5 &#x02013; 6.5 mg, 3 to 4 times a day</p></list-item><list-item><p>Spray &#x02013; 0.4 to 0.8 mg, 1 to 3 times a day; max 3 actuations in 15 minutes</p></list-item><list-item><p>IV &#x02013; range from 10 to 120 micrograms/min</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Isosorbide dinitrate
<list list-type="bullet"><list-item><p>Tablet &#x02013; 10 to 40 mg 3 times a day</p></list-item><list-item><p>Sublingual tablet &#x02013; 2.5 to 10 mg</p></list-item><list-item><p>Spray &#x02013; 1.25 mg per dose</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Isosorbide mononitrate
<list list-type="bullet"><list-item><p>Tablet &#x02013; 20 mg twice daily, 7 hours apart</p></list-item><list-item><p>Tablet (Sustained release) &#x02013; 30 to 120 daily; max daily dose 240 mg daily</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25895.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Main adverse effects from nitrate use come from dilation of the venous blood vessels. Other side effects can be reflexes from the activation of the sympathetic nervous system or re-exposure after withdrawal. These side effects include<xref ref-type="bibr" rid="article-25895.r3">[3]</xref><xref ref-type="bibr" rid="article-25895.r7">[7]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Headaches (greater than 10%)</p>
          </list-item>
          <list-item>
            <p>Hypotension (0.1 to 10%)</p>
          </list-item>
          <list-item>
            <p>Cutaneous flushing (0.1 to 10%)</p>
          </list-item>
          <list-item>
            <p>Syncope (0.1 to 10%)</p>
          </list-item>
          <list-item>
            <p>Reflex tachycardia (0.1 to 10%)</p>
          </list-item>
          <list-item>
            <p>Methemoglobinemia (rare)</p>
          </list-item>
          <list-item>
            <p>Monday disease (tachycardia, headache, and dizziness during re-exposure)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25895.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Several contraindications exist for the use of nitrate.<xref ref-type="bibr" rid="article-25895.r3">[3]</xref> They are the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Allergy to nitrates</p>
          </list-item>
          <list-item>
            <p>Concomitant use of phosphodiesterase (PDE) inhibitors such as tadalafil and sildenafil</p>
          </list-item>
          <list-item>
            <p>Right ventricular infarction</p>
          </list-item>
          <list-item>
            <p>Hypertrophic cardiomyopathy</p>
          </list-item>
        </list>
        <p>PDE inhibitors and nitrates both cause vasodilation, and concomitant use may cause severe hypotension. Healthcare providers should make sure to inquire if the patients have erectile dysfunction and if they are taking medications for it.</p>
        <p>Poor right ventricular contractility causes the patients to be pre-load sensitive, and nitrates may cause severe hypotension. Decreased left ventricular volume from decreased preload will worsen the outflow tract obstruction.</p>
        <p>The following are conditions that require care with nitrate administration:</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients on chronic diuretic therapy</p>
          </list-item>
          <list-item>
            <p>Patients with low systolic blood pressure</p>
          </list-item>
          <list-item>
            <p>Patients with autonomic nervous system dysregulation</p>
          </list-item>
          <list-item>
            <p>Pregnancy and breastfeeding.</p>
          </list-item>
        </list>
        <p>Patients on diuretic therapy can be volume depleted and can develop hypotension.</p>
        <p>Patients who have low systolic blood pressure can develop severe hypotension.</p>
        <p>Elderly patients and patients with autonomic nervous system dysregulation have a higher risk of postural hypotension.</p>
        <p>Nitrates have not been evaluated fully in pregnancy and breastfeeding, so they should be avoided.</p>
      </sec>
      <sec id="article-25895.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Generally, nitrate use does not necessitate monitoring. However, if the patient is on diuretic therapy or has low systolic blood pressure, blood pressure, and heart rate requires monitoring.&#x000a0;Other medications may be used in conjunction with nitrates to treat reflexive mechanisms. Beta-blockers can be used with nitrates to prevent reflex tachycardia.<xref ref-type="bibr" rid="article-25895.r2">[2]</xref> Hydralazine can be used with nitrate to improve symptoms and mortality in heart failure patients.<xref ref-type="bibr" rid="article-25895.r2">[2]</xref></p>
        <p>Nitrate tolerance is a significant problem regarding chronic nitrate use.<xref ref-type="bibr" rid="article-25895.r3">[3]</xref> Tolerance may develop quickly within 12 to 24 hours, and nitrates lose its clinical effects; this necessitates nitrate-free or low nitrate level for 10 to 12 hours a day. Health care professionals should inform the patients of anginal episodes during the nitrate-free periods as well. Chronic nitrate use without rest periods results in poor symptom control in addition to endothelial dysfunction due to the accumulation of free radicals.<xref ref-type="bibr" rid="article-25895.r7">[7]</xref> Rebound angina may also occur from nitrate withdrawal.</p>
      </sec>
      <sec id="article-25895.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There is currently no evidence of the teratogenicity or carcinogenicity potential of nitrate.</p>
        <p>Methemoglobinemia can be caused by nitrate toxicity in rare cases.<xref ref-type="bibr" rid="article-25895.r7">[7]</xref> Generally, supportive care and cessation of nitrate should be sufficient for most cases of methemoglobinemia. Methylene blue is an effective antidote if needed.<xref ref-type="bibr" rid="article-25895.r9">[9]</xref></p>
      </sec>
      <sec id="article-25895.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Due to high prevalence and high rates of readmission compared to other chronic medical diseases, coronary heart disease in patients must receive treatment with significant interprofessional communication for not only symptomatic improvement but also mortality reduction.</p>
        <p>Nitrates are the first-line medication for angina, one of the main symptoms of coronary heart disease. Multiple health care professionals such as general practitioners (GP), home care workers, pharmacists, and dieticians can work together to improve patients&#x02019; quality of life and prevent exacerbation of the disease.<xref ref-type="bibr" rid="article-25895.r10">[10]</xref> Communication between the providers can prevent adverse drug interactions when prescribing nitrates, and limit side effects in patients who are at increased risk. Since chronic heart failure and erectile dysfunction frequently occur concomitantly,<xref ref-type="bibr" rid="article-25895.r11">[11]</xref> pharmacists, nurses, and GPs should ensure nitrates therapy is not an option if the patient is on PDE inhibitors. Home care professional nurses should also&#x000a0;work with GPs for elderly patients who are prone to hypotension to prevent syncope. [Level III]</p>
        <p>Nursing can verify medication compliance at each visit and monitor for adverse events, reporting these to the prescribing clinician. Pharmacists should verify both dose and dose form prior to dispensing, and also alert the prescriber should there be any discrepancies. Pharmacists should also perform medication reconciliation and communicate any issues to the nurse or prescribing clinician.</p>
        <p>Nitrate therapy requires an interprofessional team approach, including physicians, specialists, specialty-trained nurses, and pharmacists, all collaborating across disciplines to achieve optimal patient results. [Level 5]</p>
      </sec>
      <sec id="article-25895.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25895&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25895">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25895/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25895">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25895.s11">
        <title>References</title>
        <ref id="article-25895.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fran&#x000e7;a-Silva</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Balarini</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Cruz</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Rampelotto</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Braga</surname>
                <given-names>VA</given-names>
              </name>
            </person-group>
            <article-title>Organic nitrates: past, present and future.</article-title>
            <source>Molecules</source>
            <year>2014</year>
            <month>Sep</month>
            <day>24</day>
            <volume>19</volume>
            <issue>9</issue>
            <fpage>15314</fpage>
            <page-range>15314-23</page-range>
            <pub-id pub-id-type="pmid">25255247</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25895.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daiber</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>M&#x000fc;nzel</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Organic Nitrate Therapy, Nitrate Tolerance, and Nitrate-Induced Endothelial Dysfunction: Emphasis on Redox Biology and Oxidative Stress.</article-title>
            <source>Antioxid Redox Signal</source>
            <year>2015</year>
            <month>Oct</month>
            <day>10</day>
            <volume>23</volume>
            <issue>11</issue>
            <fpage>899</fpage>
            <page-range>899-942</page-range>
            <pub-id pub-id-type="pmid">26261901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25895.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boden</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Finn</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Peacock</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Thadani</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Zimmerman</surname>
                <given-names>FH</given-names>
              </name>
            </person-group>
            <article-title>Nitrates as an integral part of optimal medical therapy and cardiac rehabilitation for stable angina: review of current concepts and therapeutics.</article-title>
            <source>Clin Cardiol</source>
            <year>2012</year>
            <month>May</month>
            <volume>35</volume>
            <issue>5</issue>
            <fpage>263</fpage>
            <page-range>263-71</page-range>
            <pub-id pub-id-type="pmid">22528319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25895.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parker</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>JO</given-names>
              </name>
            </person-group>
            <article-title>Nitrate therapy for stable angina pectoris.</article-title>
            <source>N Engl J Med</source>
            <year>1998</year>
            <month>Feb</month>
            <day>19</day>
            <volume>338</volume>
            <issue>8</issue>
            <fpage>520</fpage>
            <page-range>520-31</page-range>
            <pub-id pub-id-type="pmid">9468470</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25895.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000fc;nzel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Steven</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Daiber</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Organic nitrates: update on mechanisms underlying vasodilation, tolerance and endothelial dysfunction.</article-title>
            <source>Vascul Pharmacol</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>63</volume>
            <issue>3</issue>
            <fpage>105</fpage>
            <page-range>105-13</page-range>
            <pub-id pub-id-type="pmid">25446162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25895.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boden</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Padala</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Cabral</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Buschmann</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Sidhu</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Role of short-acting nitroglycerin in the management of ischemic heart disease.</article-title>
            <source>Drug Des Devel Ther</source>
            <year>2015</year>
            <volume>9</volume>
            <fpage>4793</fpage>
            <page-range>4793-805</page-range>
            <pub-id pub-id-type="pmid">26316714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25895.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tarkin</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kaski</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Vasodilator Therapy: Nitrates and Nicorandil.</article-title>
            <source>Cardiovasc Drugs Ther</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>367</fpage>
            <page-range>367-378</page-range>
            <pub-id pub-id-type="pmid">27311574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25895.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zimrin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Reichek</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bogin</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Aurigemma</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Douglas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Berko</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fung</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Antianginal effects of intravenous nitroglycerin over 24 hours.</article-title>
            <source>Circulation</source>
            <year>1988</year>
            <month>Jun</month>
            <volume>77</volume>
            <issue>6</issue>
            <fpage>1376</fpage>
            <page-range>1376-84</page-range>
            <pub-id pub-id-type="pmid">3131041</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25895.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bojar</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Rastegar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Payne</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Harkness</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>England</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Stetz</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Weiner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cleveland</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Methemoglobinemia from intravenous nitroglycerin: a word of caution.</article-title>
            <source>Ann Thorac Surg</source>
            <year>1987</year>
            <month>Mar</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>332</fpage>
            <page-range>332-4</page-range>
            <pub-id pub-id-type="pmid">3103557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25895.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jaarsma</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Inter-professional team approach to patients with heart failure.</article-title>
            <source>Heart</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>91</volume>
            <issue>6</issue>
            <fpage>832</fpage>
            <page-range>832-8</page-range>
            <pub-id pub-id-type="pmid">15894793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25895.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwarz</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Rastogi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kapur</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sulemanjee</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Erectile dysfunction in heart failure patients.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2006</year>
            <month>Sep</month>
            <day>19</day>
            <volume>48</volume>
            <issue>6</issue>
            <fpage>1111</fpage>
            <page-range>1111-9</page-range>
            <pub-id pub-id-type="pmid">16978992</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
